Merck & Co Inc
PAR:MRK

Watchlist Manager
Merck & Co Inc Logo
Merck & Co Inc
PAR:MRK
Watchlist
Price: 100.7242 EUR -0.67%
Market Cap: 256.9B EUR

Relative Value

The Relative Value of one MRK stock under the Base Case scenario is hidden EUR. Compared to the current market price of 100.7242 EUR, Merck & Co Inc is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

MRK Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Multiples Across Competitors

MRK Competitors Multiples
Merck & Co Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Merck & Co Inc
PAR:MRK
271.6B EUR 4.2 14.3 10.1 12
US
Eli Lilly and Co
NYSE:LLY
1T USD 17.3 55.9 37.5 40.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 5.8 -157.8 0.4 1.9
US
Johnson & Johnson
NYSE:JNJ
525.7B USD 5.6 19.6 13.7 16.8
CH
Roche Holding AG
SIX:ROG
277B CHF 4.5 29.4 12.5 14.6
UK
AstraZeneca PLC
LSE:AZN
210.3B GBP 4.9 30.2 19.9 29.1
CH
Novartis AG
SIX:NOVN
220.9B CHF 5 19.4 15.4 19.8
DK
Novo Nordisk A/S
CSE:NOVO B
1.8T DKK 5.8 17.5 12.1 14.1
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 344.9 865
US
Pfizer Inc
NYSE:PFE
148.4B USD 2.4 15.1 7.6 10.4
FR
Sanofi SA
PAR:SAN
97.1B EUR 1.4 7 6.4 6.4
P/E Multiple
Earnings Growth PEG
US
Merck & Co Inc
PAR:MRK
Average P/E: 23.2
14.3
15%
1
US
Eli Lilly and Co
NYSE:LLY
55.9
54%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -157.8 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.6
6%
3.3
CH
Roche Holding AG
SIX:ROG
29.4
29%
1
UK
AstraZeneca PLC
LSE:AZN
30.2
37%
0.8
CH
Novartis AG
SIX:NOVN
19.4
17%
1.1
DK
Novo Nordisk A/S
CSE:NOVO B
17.5
3%
5.8
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
US
Pfizer Inc
NYSE:PFE
15.1
27%
0.6
FR
Sanofi SA
PAR:SAN
7
26%
0.3
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Merck & Co Inc
PAR:MRK
Average EV/EBITDA: 43.7
10.1
6%
1.7
US
Eli Lilly and Co
NYSE:LLY
37.5
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
0.4
36%
0
US
Johnson & Johnson
NYSE:JNJ
13.7
-1%
N/A
CH
Roche Holding AG
SIX:ROG
12.5
5%
2.5
UK
AstraZeneca PLC
LSE:AZN
19.9
10%
2
CH
Novartis AG
SIX:NOVN
15.4
6%
2.6
DK
Novo Nordisk A/S
CSE:NOVO B
12.1
1%
12.1
IE
E
Endo International PLC
LSE:0Y5F
344.9
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.6
0%
N/A
FR
Sanofi SA
PAR:SAN
6.4
8%
0.8
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Merck & Co Inc
PAR:MRK
Average EV/EBIT: 93.7
12
8%
1.5
US
Eli Lilly and Co
NYSE:LLY
40.1
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
1.9
98%
0
US
Johnson & Johnson
NYSE:JNJ
16.8
4%
4.2
CH
Roche Holding AG
SIX:ROG
14.6
6%
2.4
UK
AstraZeneca PLC
LSE:AZN
29.1
23%
1.3
CH
Novartis AG
SIX:NOVN
19.8
12%
1.7
DK
Novo Nordisk A/S
CSE:NOVO B
14.1
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
865
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.4
7%
1.5
FR
Sanofi SA
PAR:SAN
6.4
15%
0.4